Galapagos is a global biotechnology company with operations in Europe and the US dedicated to developing transformational medicines for more years of life and quality of life. Focusing on high unmet medical needs, we synergize the most compelling science, technology, and collaborative approaches to create a deep pipeline of best-in-class small molecules, CAR-T therapies, and biologics in oncology and immunology.

With capabilities from lab to patient, including a decentralized T-cell manufacturing network, we are committed to challenging the status quo and delivering results for our patients, employees and shareholders.

We are listed on Euronext Amsterdam and Brussels and on NASDAQ, with ticker symbol GLPG. We have an international investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us if you have any additional questions after reviewing our website.